{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:53:36Z","timestamp":1791089616266,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.sleep.2026.109253","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:04:15Z","timestamp":1788793455000},"page":"109253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Orexin pathway modulation in narcolepsy: from Autoimmune mechanisms to nanotechnology enabled therapeutic delivery"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5615-0142","authenticated-orcid":false,"given":"Muhammad","family":"Irfan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5375-1509","authenticated-orcid":false,"given":"Ayesha","family":"Nasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor","family":"Azmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiza","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8248-1997","authenticated-orcid":false,"given":"Samreen","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.sleep.2026.109253_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13631","article-title":"Narcolepsy","volume":"31","author":"Barateau","year":"2022","journal-title":"J Sleep Res"},{"issue":"5","key":"10.1016\/j.sleep.2026.109253_bib3","first-page":"233","article-title":"The medical and economic burden of narcolepsy: implications for managed care","volume":"10","author":"Thorpy","year":"2017","journal-title":"American health & drug benefits"},{"issue":"6","key":"10.1016\/j.sleep.2026.109253_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13383","article-title":"Health\u2010related quality of life in narcolepsy: a systematic review and meta\u2010analysis","volume":"30","author":"Tadrous","year":"2021","journal-title":"J Sleep Res"},{"issue":"25","key":"10.1016\/j.sleep.2026.109253_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1935.02760510023006","article-title":"The use of benzedrine for the treatment of narcolepsy","volume":"105","author":"Prinzmetal","year":"1935","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.sleep.2026.109253_bib8","first-page":"557","article-title":"Narcolepsy: current treatment options and future approaches","volume":"4","author":"Billiard","year":"2008","journal-title":"Neuropsychiatric Dis Treat"},{"issue":"2","key":"10.1016\/j.sleep.2026.109253_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1389-9457(99)00014-3","article-title":"A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy","volume":"1","author":"Moldofsky","year":"2000","journal-title":"Sleep Med"},{"issue":"5","key":"10.1016\/j.sleep.2026.109253_bib10","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/med.21959","article-title":"Targeting orexin receptors: recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders","volume":"43","author":"Bonifazi","year":"2023","journal-title":"Med Res Rev"},{"issue":"5","key":"10.1016\/j.sleep.2026.109253_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/pharmrev.123.000953","article-title":"International union of basic and clinical pharmacology CXIV: orexin receptor function, nomenclature and pharmacology","volume":"76","author":"Kukkonen","year":"2024","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12987-025-00638-9","article-title":"Sleep disorders and Alzheimer's disease: relationship and mechanisms involving neuroinflammation, orexin and A\u03b2","volume":"22","author":"Zhang","year":"2025","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.sleep.2026.109253_bib13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/d41573-025-00131-w","article-title":"Leading orexin receptor agonist clears phase III for narcolepsy","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12951-025-03572-y","article-title":"Recent advances of engineering cell membranes for nanomedicine delivery across the blood\u2013brain barrier","volume":"23","author":"Yuan","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.sleep.2026.109253_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125186","article-title":"Advancing neurological disorders therapies: organic nanoparticles as a key to blood-brain barrier penetration","volume":"670","author":"Sadat Razavi","year":"2025","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12938-025-01474-6","article-title":"Recent advances in potential drug nanocarriers for CNS disorders: a review","volume":"24","author":"Saraswathi","year":"2025","journal-title":"Biomed Eng Online"},{"issue":"10","key":"10.1016\/j.sleep.2026.109253_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.70984","article-title":"Orexin deficiency in Narcolepsy: molecular mechanisms, clinical phenotypes, and emerging therapeutic frontiers","volume":"15","author":"Rauf","year":"2025","journal-title":"Brain and Behavior"},{"key":"10.1016\/j.sleep.2026.109253_bib18","series-title":"Handbook of the biology and pathology of mental disorders","first-page":"2717","article-title":"Narcolepsy and Orexin Receptor 2","author":"Kimura","year":"2025"},{"issue":"10","key":"10.1016\/j.sleep.2026.109253_bib19","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3390\/pharmaceutics14102237","article-title":"Blood\u2013brain barrier transport of transferrin receptor-targeted nanoparticles","volume":"14","author":"Thomsen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.sleep.2026.109253_bib20","series-title":"Nanomaterials for drug delivery and neurological diseases management","first-page":"403","article-title":"Aspects of nanomedicines' safety and nanotoxicity for BrainTargeted drug delivery","author":"Dubey","year":"2024"},{"issue":"9","key":"10.1016\/j.sleep.2026.109253_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy\u2014Clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"Bassetti","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.sleep.2026.109253_bib22","series-title":"Classification of sleep disorders","first-page":"57","author":"Feti Ceti\u0307n","year":"2023"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/sleepadvances\/zpae085","article-title":"Epidemiology, patient characteristics, and treatment patterns of patients with narcolepsy in Sweden: a non-interventional study using secondary data","volume":"5","author":"Giertz","year":"2024","journal-title":"Sleep Adv"},{"issue":"5","key":"10.1016\/j.sleep.2026.109253_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/practneurol-2014-000837","article-title":"Narcolepsy: a clinical review","volume":"14","author":"Leschziner","year":"2014","journal-title":"Pract Neurol"},{"key":"10.1016\/j.sleep.2026.109253_bib25","series-title":"Narcolepsy and hypersomnia","first-page":"481","article-title":"Environmental factors in narcolepsy","author":"Billiard","year":"2006"},{"issue":"2","key":"10.1016\/j.sleep.2026.109253_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejim.2011.09.005","article-title":"Excessive daytime sleepiness and narcolepsy\u2014an approach to investigation and management","volume":"23","author":"Morrison","year":"2012","journal-title":"Eur J Intern Med"},{"issue":"9560","key":"10.1016\/j.sleep.2026.109253_bib27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","article-title":"Narcolepsy with cataplexy","volume":"369","author":"Dauvilliers","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.sleep.2026.109253_bib28","series-title":"Narcolepsy: a clinical guide","first-page":"87","article-title":"Hypnagogic hallucinations and sleep paralysis","author":"D'Agostino","year":"2008"},{"key":"10.1016\/j.sleep.2026.109253_bib29","series-title":"Narcolepsy","first-page":"119","article-title":"Diagnostic tools for narcolepsy: sleep studies, multiple sleep latency test, and more","author":"BaHammam","year":"2025"},{"issue":"6","key":"10.1016\/j.sleep.2026.109253_bib31","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"issue":"1pt1","key":"10.1016\/j.sleep.2026.109253_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2869.2010.00870.x","article-title":"Relationship between clinical characteristics of narcolepsy and CSF orexin\u2010A levels","volume":"20","author":"Nakamura","year":"2011","journal-title":"J Sleep Res"},{"issue":"2","key":"10.1016\/j.sleep.2026.109253_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0306-4522(02)00017-9","article-title":"Anatomical substrates of orexin\u2013dopamine interactions: lateral hypothalamic projections to the ventral tegmental area","volume":"111","author":"Fadel","year":"2002","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/157015909787602797","article-title":"Hypocretin\/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis","volume":"7","author":"Nunez","year":"2009","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0167-0115(99)00076-2","article-title":"Orexins and orexin receptors: implication in feeding behavior","volume":"85","author":"Sakurai","year":"1999","journal-title":"Regul Pept"},{"key":"10.1016\/j.sleep.2026.109253_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.931970","article-title":"The Orexin receptors: structural and anti-tumoral properties","volume":"13","author":"Couvineau","year":"2022","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.sleep.2026.109253_bib36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bph.12324","article-title":"Orexin\/hypocretin receptor signalling cascades","volume":"171","author":"Kukkonen","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0006-291X(03)00299-7","article-title":"Regulation of orexin neurons by the monoaminergic and cholinergic systems","volume":"303","author":"Yamanaka","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.sleep.2026.109253_bib41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1748-1716.2009.02008.x","article-title":"Role of orexin in the regulation of glucose homeostasis","volume":"198","author":"Tsuneki","year":"2010","journal-title":"Acta Physiol"},{"key":"10.1016\/j.sleep.2026.109253_bib42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.neubiorev.2016.06.044","article-title":"Orexin, stress and central cardiovascular control. A link with hypertension?","volume":"74","author":"Carrive","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"10.1016\/j.sleep.2026.109253_bib37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.smrv.2004.07.007","article-title":"Roles of orexin\/hypocretin in regulation of sleep\/wakefulness and energy homeostasis","volume":"9","author":"Sakurai","year":"2005","journal-title":"Sleep Med Rev"},{"issue":"11","key":"10.1016\/j.sleep.2026.109253_bib38","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1111\/j.1460-9568.2005.04121.x","article-title":"Dopaminergic regulation of orexin neurons","volume":"21","author":"Bubser","year":"2005","journal-title":"Eur J Neurosci"},{"issue":"1pt1","key":"10.1016\/j.sleep.2026.109253_bib39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2869.2010.00851.x","article-title":"Selective REM sleep deprivation in narcolepsy","volume":"20","author":"Vu","year":"2011","journal-title":"J Sleep Res"},{"issue":"12","key":"10.1016\/j.sleep.2026.109253_bib43","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.5664\/jcsm.11300","article-title":"Association between human leukocyte antigen class II-DR-DQ and narcolepsy: a case control study","volume":"20","author":"Bacelar","year":"2024","journal-title":"J Clin Sleep Med"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib44","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1038\/s41467-023-36120-z","article-title":"Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy","volume":"14","author":"Ollila","year":"2023","journal-title":"Nat Commun"},{"issue":"52","key":"10.1016\/j.sleep.2026.109253_bib45","doi-asserted-by":"crossref","first-page":"E12323","DOI":"10.1073\/pnas.1818150116","article-title":"Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy","volume":"115","author":"Luo","year":"2018","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.sleep.2026.109253_bib54","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ng.372","article-title":"Narcolepsy is strongly associated with the T-cell receptor alpha locus","volume":"41","author":"Hallmayer","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.sleep.2026.109253_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2013.02.003","article-title":"Genetic association, seasonal infections and autoimmune basis of narcolepsy","volume":"43","author":"Singh","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.sleep.2026.109253_bib48","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbi.2013.12.019","article-title":"Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: a case-control study","volume":"37","author":"Dauvilliers","year":"2014","journal-title":"Brain Behav Immun"},{"issue":"9","key":"10.1016\/j.sleep.2026.109253_bib55","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.sleep.2026.109253_bib47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1080\/00207454.2016.1212854","article-title":"Neuroinflammation pathways: a general review","volume":"127","author":"Shabab","year":"2017","journal-title":"Int J Neurosci"},{"issue":"6","key":"10.1016\/j.sleep.2026.109253_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awab455","article-title":"Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsy","volume":"145","author":"Bernard-Valnet","year":"2022","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.sleep.2026.109253_bib50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.sleep.2026.109253_bib51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbi.2015.03.004","article-title":"Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset","volume":"49","author":"Kornum","year":"2015","journal-title":"Brain Behav Immun"},{"issue":"1\u20132","key":"10.1016\/j.sleep.2026.109253_bib52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jneuroim.2006.02.010","article-title":"Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy","volume":"174","author":"Overeem","year":"2006","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.sleep.2026.109253_bib53","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1172\/JCI41366","article-title":"Elevated Tribbles homolog 2\u2013specific antibody levels in narcolepsy patients","volume":"120","author":"Cvetkovic-Lopes","year":"2010","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.sleep.2026.109253_bib56","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1111\/ene.14888","article-title":"European guideline and expert statements on the management of narcolepsy in adults and children","volume":"28","author":"Bassetti","year":"2021","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.sleep.2026.109253_bib57","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40263-025-01175-7","article-title":"Comparative efficacy and safety of multiple wake-promoting agents for the treatment of residual sleepiness in obstructive sleep apnea despite continuous positive airway pressure: a systematic review and network meta-analysis of randomized controlled trials","volume":"39","author":"Tanayapong","year":"2025","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.sleep.2026.109253_bib58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/sleep\/24.3.282","article-title":"Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study","volume":"24","author":"Larrosa","year":"2001","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.sleep.2026.109253_bib59","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics10040269","article-title":"Blood-brain delivery methods using nanotechnology","volume":"10","author":"Teleanu","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.sleep.2026.109253_bib7","series-title":"Neurology","article-title":"The safety profile of modafinil in disorders of sleep and wakefulness","author":"Thorpy","year":"2004"},{"issue":"12","key":"10.1016\/j.sleep.2026.109253_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.71116","article-title":"Narcolepsy: pathophysiology, diagnosis, management, and future directions, a narrative review","volume":"15","author":"Hastings","year":"2025","journal-title":"Brain Behav"},{"issue":"23","key":"10.1016\/j.sleep.2026.109253_bib63","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1073\/pnas.1722686115","article-title":"Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy","volume":"115","author":"Kaushik","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.sleep.2026.109253_bib5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/NSS.S162762","article-title":"Living with narcolepsy: current management strategies, future prospects, and overlooked real-life concerns","author":"Barker","year":"2020","journal-title":"Nat Sci Sleep"},{"issue":"7","key":"10.1016\/j.sleep.2026.109253_bib60","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.sleep.2026.109253_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.peptides.2015.03.010","article-title":"Peptides and the blood\u2013brain barrier","volume":"72","author":"Banks","year":"2015","journal-title":"Peptides"},{"key":"10.1016\/j.sleep.2026.109253_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101665","article-title":"Targeting the transferrin receptor for brain drug delivery","volume":"181","author":"Johnsen","year":"2019","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.sleep.2026.109253_bib65","series-title":"Fundamentals of pharmaceutical nanoscience","first-page":"241","article-title":"Nanomedicines for delivery across the blood\u2013brain barrier","author":"Lalatsa","year":"2024"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib64","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s40001-024-01915-3","article-title":"Alzheimer's disease and drug delivery across the blood\u2013brain barrier: approaches and challenges","volume":"29","author":"Iqbal","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.sleep.2026.109253_bib66","series-title":"PEGylated nanocarriers in medicine and pharmacy","first-page":"295","article-title":"PEGylated nanocarriers for protein and peptide delivery","author":"Agnihotri","year":"2025"},{"key":"10.1016\/j.sleep.2026.109253_bib67","series-title":"Nanoparticles in modern neurological treatment","first-page":"109","article-title":"Nanoparticle-Mediated treatment for brain tumours","author":"Kanet","year":"2025"},{"key":"10.1016\/j.sleep.2026.109253_bib68","series-title":"Nanomaterials for drug delivery and neurological diseases management","first-page":"3","article-title":"Nanocarriers for drug delivery: general characteristics","author":"Sillu","year":"2024"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib70","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41531-025-01081-1","article-title":"Revamping Parkinson's disease therapy using PLGA-based drug delivery systems","volume":"11","author":"Lababidi","year":"2025","journal-title":"npj Parkinson's Dis"},{"key":"10.1016\/j.sleep.2026.109253_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114485","article-title":"Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: crossing or circumventing the blood\u2013brain barrier (BBB) to manage neurological disorders","volume":"189","author":"Correia","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.sleep.2026.109253_bib71","series-title":"Current trends in exosomes as therapeutic drug delivery systems","author":"Alsaidan","year":"2025"},{"issue":"4","key":"10.1016\/j.sleep.2026.109253_bib72","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17425247.2018.1429401","article-title":"Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery","volume":"15","author":"Battaglia","year":"2018","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.sleep.2026.109253_bib73","doi-asserted-by":"crossref","first-page":"p155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erd\u0151","year":"2018","journal-title":"Brain Res Bull"},{"issue":"3","key":"10.1016\/j.sleep.2026.109253_bib74","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/nano9030371","article-title":"Nanomaterials for drug delivery to the central nervous system","volume":"9","author":"Teleanu","year":"2019","journal-title":"Nanomaterials"},{"issue":"4","key":"10.1016\/j.sleep.2026.109253_bib75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/2231-4040.90876","article-title":"A review on mucoadhesive polymer used in nasal drug delivery system","volume":"2","author":"Chaturvedi","year":"2011","journal-title":"J Adv Pharm Technol Res"},{"key":"10.1016\/j.sleep.2026.109253_bib76","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijbiomac.2016.04.076","article-title":"Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route","volume":"89","author":"Shah","year":"2016","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"10.1016\/j.sleep.2026.109253_bib77","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1208\/s12249-024-02917-4","article-title":"PLGA nanoparticles based mucoadhesive nasal in Situ Gel for enhanced brain delivery of topiramate","volume":"25","author":"Tanna","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"24","key":"10.1016\/j.sleep.2026.109253_bib78","doi-asserted-by":"crossref","first-page":"20326","DOI":"10.1021\/acsami.8b04613","article-title":"Brain targeting delivery facilitated by ligand-functionalized layered double hydroxide nanoparticles","volume":"10","author":"Chen","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"issue":"10","key":"10.1016\/j.sleep.2026.109253_bib84","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41563-024-02114-5","article-title":"Blood\u2013brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system","volume":"24","author":"Wang","year":"2025","journal-title":"Nat Mater"},{"issue":"4","key":"10.1016\/j.sleep.2026.109253_bib89","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3892\/ijo.2025.5789","article-title":"Nanoparticle-based delivery systems for targeted therapy in brain tumors: progress, challenges and perspectives","volume":"67","author":"Si","year":"2025","journal-title":"Int J Oncol"},{"key":"10.1016\/j.sleep.2026.109253_bib86","first-page":"331","article-title":"Chitosan-Based nanoparticles for brain drug delivery","author":"Askari","year":"2026","journal-title":"Chitosan-Based Drug Delivery Systems"},{"issue":"3","key":"10.1016\/j.sleep.2026.109253_bib82","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/pharmaceutics14030672","article-title":"Strategies for targeted delivery of exosomes to the brain: advantages and challenges","volume":"14","author":"Choi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.sleep.2026.109253_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/sus2.222","article-title":"Construction of an intranasal drug delivery system with hypothalamustargeting nanoparticles","volume":"4","author":"Rao","year":"2024","journal-title":"SusMat"},{"issue":"13","key":"10.1016\/j.sleep.2026.109253_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202500521","article-title":"Blood\u2010Brain barrier\u2010penetrating nanocarriers enable microglial\u2010specific drug delivery in hypothalamic neuroinflammation","volume":"14","author":"Goo","year":"2025","journal-title":"Adv Healthcare Mater"},{"issue":"7","key":"10.1016\/j.sleep.2026.109253_bib81","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1039\/D4RA07798A","article-title":"Metal nanoparticles in neuroinflammation: impact on microglial dynamics and CNS function","volume":"15","author":"Masood","year":"2025","journal-title":"RSC Adv"},{"key":"10.1016\/j.sleep.2026.109253_bib83","series-title":"Blood-Brain barrier","first-page":"145","article-title":"Cell-Penetrating peptide-decorated nanovectors for nose-to-brain delivery: a new treatment option for CNS diseases","author":"Sonvico","year":"2025"},{"issue":"44","key":"10.1016\/j.sleep.2026.109253_bib85","doi-asserted-by":"crossref","first-page":"30293","DOI":"10.1021\/acsnano.4c05169","article-title":"Widespread gene editing in the brain via in utero delivery of mRNA using acid-degradable lipid nanoparticles","volume":"18","author":"Gao","year":"2024","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.sleep.2026.109253_bib87","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/biomedicines14030571","article-title":"Intranasal drug delivery in neuropharmacology: advances in brain-targeted therapies and bioethical challenges","volume":"14","author":"Damian","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.sleep.2026.109253_bib88","series-title":"Nose to brain delivery of dapoxetine-loaded PLGA nanoparticle for treatment of premature ejaculation distress in normal and diabetic rats with in silico targeting brain FOX and serotonin proteins","first-page":"1","author":"El-Ela","year":"2025"},{"key":"10.1016\/j.sleep.2026.109253_bib90","doi-asserted-by":"crossref","DOI":"10.1039\/D5CC07306E","article-title":"Targeted drug delivery: designing nanocarriers for improved therapeutic action","author":"Hussain","year":"2026","journal-title":"Chem Commun"},{"key":"10.1016\/j.sleep.2026.109253_bib113","article-title":"Progress on drug nanoparticle manufacturing: exploring the adaptability of batch bottom-up approaches to continuous manufacturing","volume":"111","author":"Costa","year":"2025","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1015","key":"10.1016\/j.sleep.2026.109253_bib114","article-title":"Overview of modern methods for nanoparticle production","volume":"2025","author":"Kalinin","year":"2025","journal-title":"ChemRxiv"},{"key":"10.1016\/j.sleep.2026.109253_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleep.2025.106646","article-title":"Factors associated with diagnostic delay in narcolepsy: Real-world data from a Korean multicenter study","volume":"133","author":"Jung","year":"2025","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2026.109253_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleep.2025.106505","article-title":"Detection of reduced orexinA\/hypocretin-1 and its fragments by orexin-A \u201cgold-standard\u201d radioimmunoassay","volume":"131","author":"Kukkonen","year":"2025","journal-title":"Sleep Med"},{"issue":"3","key":"10.1016\/j.sleep.2026.109253_bib94","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/cn300159e","article-title":"Detection of orexin A neuropeptide in biological fluids using a zinc oxide field effect transistor","volume":"4","author":"Hagen","year":"2013","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"10.1016\/j.sleep.2026.109253_bib95","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/pcn.12780","article-title":"Measurement of cerebrospinal fluid orexin-A (hypocretin-1) by enzyme-linked immunosorbent assay: a comparison with radioimmunoassay","volume":"72","author":"Ono","year":"2018","journal-title":"Psychiatr Clin Neurosci"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib104","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41467-023-36083-1","article-title":"Gold nanoparticle-enhanced X-ray microtomography of the rodent reveals region-specific cerebrospinal fluid circulation in the brain","volume":"14","author":"Pan","year":"2023","journal-title":"Nat Commun"},{"issue":"27","key":"10.1016\/j.sleep.2026.109253_bib105","doi-asserted-by":"crossref","first-page":"12421","DOI":"10.1039\/D5SC01588J","article-title":"Ultra-high resolution magnetic resonance microscopy of in situ gadolinium gold nanoparticle-labeled cells in the rat brain","volume":"16","author":"Kisel","year":"2025","journal-title":"Chem Sci"},{"issue":"4","key":"10.1016\/j.sleep.2026.109253_bib96","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/00365513.2024.2369992","article-title":"Evaluating routine blood and cerebrospinal fluid samples in narcolepsy patients","volume":"84","author":"Haubjerg \u00d8sterby","year":"2024","journal-title":"Scand J Clin Lab Investig"},{"issue":"3","key":"10.1016\/j.sleep.2026.109253_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.252","article-title":"Multiomics analysis of human peripheral blood reveals marked molecular profiling changes caused by one night of sleep deprivation","volume":"4","author":"Chen","year":"2020","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib98","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s44276-025-00176-9","article-title":"Blood Clock Correlation Distance (BloodCCD) as a novel marker to detect circadian rhythm disruption in cancer survivors with insomnia","volume":"3","author":"Altman","year":"2025","journal-title":"BJC Rep"},{"issue":"9","key":"10.1016\/j.sleep.2026.109253_bib99","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsae083","article-title":"The Swiss Primary Hypersomnolence and Narcolepsy Cohort Study: feasibility of long-term monitoring with Fitbit smartwatches in central disorders of hypersomnolence and extraction of digital biomarkers in narcolepsy","volume":"47","author":"Gnarra","year":"2024","journal-title":"Sleep"},{"issue":"12","key":"10.1016\/j.sleep.2026.109253_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/ph16121721","article-title":"Single and multitarget systems for drug delivery and detection: Up-to-Date strategies for brain disorders","volume":"16","author":"Grosso","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.sleep.2026.109253_bib101","article-title":"Nanostructures and nanoparticles as medical diagnostic imaging contrast agents: a review","volume":"40","author":"Mhlanga","year":"2024","journal-title":"Mater Today Chem"},{"key":"10.1016\/j.sleep.2026.109253_bib102","series-title":"Recent progress and development in nanostructures","article-title":"Iron oxide nanoparticles application in toxicity therapeutics of CNS disorders indicated by molecular MRI","author":"Wu","year":"2025"},{"key":"10.1016\/j.sleep.2026.109253_bib103","first-page":"7","article-title":"Phenotype and function of human monocytes remain mainly unaffected by very small superparamagnetic iron oxide particles","author":"Hussein","year":"2025","journal-title":"Front Nanotechnol"},{"issue":"1","key":"10.1016\/j.sleep.2026.109253_bib106","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s11671-024-04118-1","article-title":"Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines","volume":"19","author":"Havelikar","year":"2024","journal-title":"Discover Nano"},{"issue":"15","key":"10.1016\/j.sleep.2026.109253_bib107","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1080\/17435889.2025.2533107","article-title":"Regulating nanomedicines: challenges, opportunities, and the path forward","volume":"20","author":"Mangla","year":"2025","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.sleep.2026.109253_bib108","first-page":"12","article-title":"Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks","author":"Rodr\u00edguez-G\u00f3mez","year":"2025","journal-title":"Front Med"},{"issue":"11","key":"10.1016\/j.sleep.2026.109253_bib109","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/17425247.2025.2556979","article-title":"Explicit analysis of in vivo, meterological and statistical hurdles in successful clinical translation of targeted nanomedicines and plausible remedial strategies","volume":"22","author":"Khan","year":"2025","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"10.1016\/j.sleep.2026.109253_bib110","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","article-title":"A translational framework to DELIVER nanomedicines to the clinic","volume":"19","author":"Joyce","year":"2024","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"10.1016\/j.sleep.2026.109253_bib111","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.apsb.2025.01.014","article-title":"Deliver: the core principles for the clinic translation of nanomedicines","volume":"15","author":"Hu","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.sleep.2026.109253_bib112","series-title":"Commercial scale production of nanomedicines","first-page":"1","article-title":"Challenges for commercial translation of nanomedicines: from lab scale to production scale","author":"Khopade","year":"2025"},{"key":"10.1016\/j.sleep.2026.109253_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbscr.2025.100137","article-title":"Neuroimaging findings in sleep disorders: a review article","volume":"20","author":"Kavehee","year":"2026","journal-title":"Neurobiology of Sleep and Circadian Rhythms"},{"issue":"2","key":"10.1016\/j.sleep.2026.109253_bib116","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","article-title":"The neurobiological basis of narcolepsy","volume":"20","author":"Mahoney","year":"2019","journal-title":"Nat Rev Neurosci"},{"issue":"19","key":"10.1016\/j.sleep.2026.109253_bib117","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa2405847","article-title":"Oveporexton, an oral orexin receptor 2-Selective agonist, in Narcolepsy type 1","volume":"392","author":"Dauvilliers","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sleep.2026.109253_bib118","series-title":"Chapter 29 - emerging therapies for narcolepsy: immunotherapy, gene therapy, and beyond","first-page":"535","author":"Swick","year":"2025"},{"issue":"11","key":"10.1016\/j.sleep.2026.109253_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47110874","article-title":"Animal models of Narcolepsy: from orexin deficiency to immune mechanisms and regenerative therapies","volume":"47","author":"Arias-Carri\u00f3n","year":"2025","journal-title":"Curr Issues Mol Biol"},{"issue":"7","key":"10.1016\/j.sleep.2026.109253_bib120","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1021\/acs.molpharmaceut.5c00062","article-title":"Revolutionizing neurological therapies: the multifaceted potential of Zein-Based nanoparticles for brain-targeted drug delivery","volume":"22","author":"Narayan","year":"2025","journal-title":"Mol Pharm"},{"key":"10.1016\/j.sleep.2026.109253_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123138","article-title":"Advanced nanoparticle engineering for precision therapeutics of brain diseases","volume":"318","author":"Ismail","year":"2025","journal-title":"Biomaterials"},{"issue":"15","key":"10.1016\/j.sleep.2026.109253_bib122","article-title":"Nanoodor particles deliver drugs to central nervous System via Olfactory pathway","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.sleep.2026.109253_bib123","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/NSS.S275931","article-title":"Reviewing the clinical implications of treating Narcolepsy as an autoimmune disorder","volume":"13","author":"Giannoccaro","year":"2021","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.sleep.2026.109253_bib124","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.sleep.2023.12.005","article-title":"Connecting the dots: an updated review of the role of autoimmunity in narcolepsy and emerging immunotherapeutic approaches","volume":"113","author":"Valizadeh","year":"2024","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2026.109253_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115606","article-title":"Nanomedicine for targeting brain Neurodegeneration: critical barriers and circadian rhythm considerations","volume":"222","author":"Pineiro-Alonso","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.sleep.2026.109253_bib126","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/pharmaceutics17070899","article-title":"Overview of preclinical and clinical trials of nanoparticles for the treatment of brain metastases","volume":"17","author":"Izhar","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.sleep.2026.109253_bib127","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.apsb.2025.01.014","article-title":"DELIVER: the core principles for the clinic translation of nanomedicines","volume":"15","author":"Hu","year":"2025","journal-title":"Acta Pharm Sin B"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945726004922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945726004922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:19:08Z","timestamp":1791087548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945726004922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":127,"alternative-id":["S1389945726004922"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2026.109253","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orexin pathway modulation in narcolepsy: from Autoimmune mechanisms to nanotechnology enabled therapeutic delivery","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2026.109253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109253"}}